Search

Your search keyword '"Neung Hwa Park"' showing total 178 results

Search Constraints

Start Over You searched for: Author "Neung Hwa Park" Remove constraint Author: "Neung Hwa Park"
178 results on '"Neung Hwa Park"'

Search Results

1. Comparative Effectiveness of a 30-minute Online Lecture on Abdominal Ultrasonography in the Post-COVID-19 era: A Multi-center Study

2. Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy

Catalog

Books, media, physical & digital resources

3. Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study

4. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

5. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

6. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir

7. Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA

8. Welfare Genome Project: A Participatory Korean Personal Genome Project With Free Health Check-Up and Genetic Report Followed by Counseling

9. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance

10. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

11. Clinical Application of Non-invasive Diagnostic Tests for Liver Fibrosis

12. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

13. Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients

14. Supplementary Figure Legends from Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR Inhibition

15. Supplementary Figure S2 from Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR Inhibition

16. Supplementary Methods from Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR Inhibition

17. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis

18. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

19. A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients

21. Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA

22. Comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving tenofovir- or entecavir-based regimens: a meta-analysis using individual patient data

23. Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy

24. Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study

25. Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B

26. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

27. Korean Genome Project: 1094 Korean personal genomes with clinical information

29. DRG2 Regulates G2/M Progression via the Cyclin B1-Cdk1 Complex

30. Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study

31. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B

32. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir

33. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir

34. Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a Korean population

35. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study

36. Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis

37. Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B

38. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection

39. Abstract 3694: TonEBP promotes chemoresistance and recurrence of hepatocellular carcinoma via DNA repair of cancer stem cells

40. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B

41. A genome-wide association study identified new variants associated with the risk of chronic hepatitis B

42. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs

43. A nationwide seroepidemiology of hepatitis C virus infection in South Korea

44. Topical application of capsaicin reduces visceral adipose fat by affecting adipokine levels in high-fat diet-induced obese mice

45. Identification of novel OCT4 genetic variant associated with the risk of chronic hepatitis B in a Korean population

46. Pallidal Signal Intensities on T1-weighted MRI are Highly Observed in Advanced Liver Cirrhosis

47. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma

48. Overexpression of bone morphogenetic protein 4 in STO fibroblast feeder cells represses the proliferation of mouse embryonic stem cells in vitro

49. The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin

50. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels